Bicycle and Genentech Forge Immuno-Oncology Collaboration Worth up to $1.7 Billion

BioSpace | February 25, 2020

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-oncology targets. The U.K. company’s proprietary discovery platform allows for rapid screening of novel targets to identify Bicycles and the ability to readily conjugate these together to create novel molecules that may overcome the potential limitations of other modalities. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, which makes Bicycles attractive candidates for drug development, the company said.

Spotlight

KeSimpulan | Optogenetics enables functional analysis of human embryonic stem cell–derived grafts in a Parkinson's disease model. Julius A Steinbeck et al (2015), Nature Biotechnology. Recent studies have shown evidence of behavioral recovery after transplantation of human pluripotent stem cell (PSC)-derived neural cells in animal models of neurological disease.

Spotlight

KeSimpulan | Optogenetics enables functional analysis of human embryonic stem cell–derived grafts in a Parkinson's disease model. Julius A Steinbeck et al (2015), Nature Biotechnology. Recent studies have shown evidence of behavioral recovery after transplantation of human pluripotent stem cell (PSC)-derived neural cells in animal models of neurological disease.

Related News

CELL AND GENE THERAPY

IsoPlexis Acquired a Large Portfolio of DNA and RNA Sequencing to Enable Integrated Single-Cell Sequencing and Proteomic Solutions

IsoPlexis | May 26, 2021

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadmap, enabling researchers to make far earlier connections in their genomic studies, straight to the proteome, which determines each organism's in vivo dynamic biology. The acquired assets will allow IsoPlexis' proprietary proteomics technologies to be integrated with newer proprietary sequencing-based technologies. The asset acquisition adds to IsoPlexis' ongoing efforts to assist its customers in more effectively simplifying complex biology to accelerate the creation of more personalized and curative advanced medicines from bench to bedside. Isoplexis' growing patent portfolio of 153 total patents filed and issued globally will now include sequencing methodologies, allowing for a new level of resolution into the connections between the genome and the proteome of cancer immunology, cell and gene therapy, neurological disease, and other areas. IsoPlexis' proprietary functional proteomics platform is the first to fully characterize and link cellular function to patient outcomes, treatment response, or disease progression using both proteomics and single-cell biology. The single-cell proteomics platform from IsoPlexis, which comprises instruments, chip consumables, and software, offers an end-to-end solution for providing a more complete view of protein function at the cellular level. The platform has been quickly embraced by the top 15 global biopharmaceutical companies in terms of revenue, as well as over half of the comprehensive cancer centers in the United States, to develop more durable therapeutics, overcome therapeutic resistance, and predict patient responses for advanced immunotherapies, cell therapies, gene therapies, vaccines, and regenerative medicines. ABOUT ISOPLEXIS IsoPlexis is a life science technology company that develops solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect to in vivo biology more directly and develop more precise and personalized therapies. Our integrated systems, which were named top innovation or design by Scientist Magazine, Fierce, BIG Innovation, Red Dot, and a variety of other magazines, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been used by researchers all over the world, including the top 15 pharmaceutical companies in the world and 45% of comprehensive cancer centers in the United States.

Read More

Ori Biotech Raises $30 Million $30 Million Series A Financing Round to Advance Innovation in Cell and Gene Therapy Manufacturing

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor syndicate was led by the experienced life sciences investment team at Northpond Ventures, a leading global science, medical, and technology-driven venture fund, alongside Octopus Ventures, a leading European venture fund. Northpond and Octopus invested alongside significant support from Ori's existing institutional investors, Amadeus Capital Partners, Delin Ventures, and Kindred Capital. "Closing a significant Series A round, during these uncertain times, further validates Ori's disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs," said Jason C. Foster, CEO of Ori Biotech. "We are excited to work with our top tier investors and development partners to bring our platform to market as fast as possible to achieve our mission of enabling patient access to life-saving cell and gene therapies." "As early investors in disruptive life sciences platform technology companies, we have seen how cutting-edge technologies like Ori's can bring significant value to the industry and lead to breakthroughs for patients," said Michael Rubin, M.D., Ph.D., Founder and CEO of Northpond Ventures. "We believe that the Ori team has developed a truly innovative technology that can enable millions of patients to gain access to these important treatments." Ori's bespoke platform was designed specifically to address the unique requirements of a new generation of personalized cell and gene therapies. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial-scale manufacturing. Its flexible platform enables increased throughput, improved quality, and decreased costs.

Read More

MEDICAL

Entopsis Exploring Strategic Alternatives for its OpsisDx™ Platform

Berkery, Noyes & Co. | October 08, 2021

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of early-stage cancers. Its IP-protected platform detects urine chemical signatures via a proprietary array, achieving clinically significant results through its proprietary machine learning algorithms. Validation studies on OpsisDxTM have initially focused on detecting early-stage cancers, and the platform has now expanded to detecting multiple other diseases in a highly scalable fashion. Now is the time to launch OpsisDxTM. There's greater acceptance of multi-disease testing platforms from a scientific, regulatory and business perspective; the industry as a whole has crossed the tipping point, We are seeking an established partner who shares our vision of empowering people with actionable, low costs and accurate healthcare information with an eye towards the long-term interests of Entopsis. - Obdulio Piloto, CEO of Entopsis Inc. AboutEntopsis, Inc., Entopsis utilizes a proprietary material science screening platform to develop cost-effective and impactful products.

Read More